Prescription of fondaparinux in hospitalised patients.
Fondaparinux is an antithrombotic agent with unique properties that may offer benefit to patients beyond the current approved indications. To explore the off-label use versus approved use of fondaparinux, we initiated a single-center registry of fondaparinux use. During the 25-month study period, 219 patients were prescribed fondaparinux: 157 (71.7%) for prophylaxis and 62 (28.3%) patients for the treatment of thrombosis. When fondaparinux was used for prophylaxis in our registry, 94% of patients had documentation of heparin-induced thrombocytopenia (HIT). Fondaparinux warrants further evaluation in patients with HIT or suspected HIT. In the meantime, its off-label use may exceed its use for FDA-approved indications.
Baroletti
Steven
S
Department of Pharmacy, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA. sbaroletti@partners.org
Labreche
Matthew
M
Niles
Matthew
M
Fanikos
John
J
Goldhaber
Samuel Z
SZ
D000328:Adult; D000368:Aged; D011307:Drug Prescriptions; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000077425:Fondaparinux; D006493:Heparin / Q000008:administration & dosage / Q000009:adverse effects; D006761:Hospitals; D006801:Humans; D008297:Male; D008875:Middle Aged; D019637:Orthopedic Procedures; D019990:Perioperative Care; D011134:Polysaccharides / Q000008:administration & dosage* / Q000009:adverse effects; D011655:Pulmonary Embolism / Q000188:drug therapy; D012042:Registries; D012307:Risk Factors; D013921:Thrombocytopenia / Q000139:chemically induced / Q000188:drug therapy*; D016896:Treatment Outcome; D054556:Venous Thromboembolism / Q000188:drug therapy* / Q000601:surgery; D020246:Venous Thrombosis / Q000188:drug therapy
D005343:Fibrinolytic Agents; D011134:Polysaccharides; D006493:Heparin; D000077425:Fondaparinux